Involvement of endocannabinoid system, inflammation and apoptosis in diabetes induced liver injury: Role of 5-HT3 receptor antagonist.
Amidohydrolases
/ genetics
Animals
Apoptosis
Diabetes Complications
/ drug therapy
Endocannabinoids
/ metabolism
Hepatitis
/ drug therapy
Humans
Inflammation
/ drug therapy
Interleukin-6
/ metabolism
Liver
/ metabolism
Male
Rats
Rats, Wistar
Receptor, Cannabinoid, CB1
/ metabolism
Serotonin 5-HT3 Receptor Antagonists
/ therapeutic use
Tropisetron
/ therapeutic use
Tumor Necrosis Factor-alpha
/ metabolism
5HT3 receptor
Apoptosis
Diabetes
Endocannabinoid system
Inflammation
Liver Injury
Metabolic diseases
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
08
10
2019
revised:
11
12
2019
accepted:
26
12
2019
pubmed:
12
1
2020
medline:
15
12
2020
entrez:
12
1
2020
Statut:
ppublish
Résumé
Confident relationships between diabetes andliver damagehave previously been established. This study was designed to evaluate hepaticinflammation, apoptosis, and endocannabinoid system alterations in diabetes with or withouttropisetrontreatment. Rats were assigned to five equal groups: control, tropisetron, diabetes, tropisetron+diabetes, and glibenclamide+diabetes (n = 7 in each group). Rats were treated with tropisetron (3 mg/kg) and glibenclamide (1 mg/kg) as a positive control for two weeks after type 1 diabetes induction.Inflammatory cytokines tumor necrosis factor-alpha and interleukin 6 (TNF-α and IL-6) levels, apoptotic cells, and fatty acid amide hydrolase (FAAH) enzyme, at both transcriptional and protein levels increased, while the gene expression of cannabinoid receptor 1 (CB1) and its protein level decreased in the diabetic liver compared to the control. Treatment with tropisetron reversed TNF-α, apoptotic index, and endocannabinoid system components. These effects were equipotent with glibenclamide, indicating that tropisetroncan protect liver tissue against diabetic disturbances. These findings strongly support the idea that diabetes-induced liver abnormality is mediated by inflammatory reactions, apoptosis, and endocannabinoid system, and that these effects can be alleviated by using tropisetron as an antioxidant and anti-inflammatory agent.
Identifiants
pubmed: 31926479
pii: S1567-5769(19)32268-4
doi: 10.1016/j.intimp.2019.106158
pii:
doi:
Substances chimiques
Endocannabinoids
0
Interleukin-6
0
Receptor, Cannabinoid, CB1
0
Serotonin 5-HT3 Receptor Antagonists
0
Tumor Necrosis Factor-alpha
0
Tropisetron
6I819NIK1W
Amidohydrolases
EC 3.5.-
fatty-acid amide hydrolase
EC 3.5.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106158Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.